We recommend the purchase of Quintiles International (QTRN @$11.84). QTRN is engaged in the provision of full-service contract research, sales and marketing and healthcare policy consulting services to the global pharmaceutical, biotechnology and medical device industries. For the nine months ended 9/02, revenues fell 2% to $1.19 billion. Net income from continuing operations totalled $59.1 million vs. a loss of $248.4 million. We estimate QTRN will earn $.67 per share on $1.6 billion in revenue this year and $.80 per share next year. Projecting an average earnings growth rate of 20%, we estimate QTRN's current PEG ratio to be .9x, substantially below those of its peers'.
moneycentral.msn.com. Click here for detailed company report.
pcyhuang
huangcapital.com
Huang's Mechanical Hedge Investing |
